Meta Pixel

News and Announcements

Startups, Would You Rather Be Unicorns Or Camels?

  • Published December 14, 2022 7:55AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

🦄 vs 🐪

Instead of the unicorn, I think the camel is a more fitting mascot for startups that are more susceptible to macroeconomic shocks.

Camels can survive the scorching desert heat, adapt to extreme variations in climate, and thrive in some of the Earth’s harshest conditions for long periods without sustenance.

When entering a desert which one would you rather be?

In tough market conditions, camels offer early-stage startups across industries and sectors valuable lessons on how to survive through economic crisis.

Founders of Camel startups understand that building a successful business starts with a strong foundation that is built to last.

They focus on being:

1) Resilient – they focus on long-term, balanced growth

2) Cautious – they’re financially conservative, hire the right team, and focus on building technology shapes industries for the better

3) Committed – they’re dedicated to business-building fundamentals and stress positive unit economics right from the get go

4) Adaptive – they’re constantly iterating based on constructive customer feedback

Investors – in the elusive search for unicorns, don’t forget startup camels.

💥

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now